Norfloxacin: in vitro activity compared with that of seven other antibacterial agents against urinary tract pathogens.
The minimal inhibitory concentrations (MICs) of norfloxacin, nalidixic acid, ampicillin, amoxycillin/clavulanic acid (4:1), mecillinam, cefaclor , sulphamethoxazole/trimethoprim (20:1) and netilmicin against 435 clinical isolates of bacterial urinary tract pathogens have been determined. An agar dilution method was employed. Norfloxacin was the most active agent in the study on a weight-for-weight basis. The drug was highly active against Enterobacteriaceae. Norfloxacin was more active than netilmicin against Pseudomonas aeruginosa (MICs less than or equal to 2 mg/l and less than or equal to 4 mg/l, respectively). Norfloxacin was also active against Gram-positive bacteria including enterococci and Staphylococcus saprophyticus (MICs less than or equal to 4 mg/l). Norfloxacin may well become a useful agent for the oral treatment of urinary tract infection, particularly as a drug for the treatment of infections caused by multiresistant organisms.
D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D001419:Bacteria / Q000187:drug effects*; D001424:Bacterial Infections / Q000188:drug therapy; D004352:Drug Resistance, Microbial; D004755:Enterobacteriaceae / Q000187:drug effects*; D006801:Humans; D007700:Kinetics; D008826:Microbial Sensitivity Tests; D009268:Nalidixic Acid / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D009643:Norfloxacin; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D013210:Staphylococcus / Q000187:drug effects; D014551:Urinary Tract / Q000382:microbiology*; D014552:Urinary Tract Infections / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D009268:Nalidixic Acid; D009643:Norfloxacin